Industry | 2009.08.24
Aperio Receives Second FDA Clearance for HER2 Image Analysis Application for Breast Cancer
VISTA, Calif.--(BUSINESS WIRE)--Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the IHC HER2 Breast Tissue Image Analysis application, available through its patented digital pathology platform. Immunohistochemistry is increasingly being used for the evaluation of therapeutic biomarkers. The IHC HER2 Breast Tissue Tunable Image Analysis applica
For more information, please visit
http://www.businesswire.com/news/home/20090824005269/en
